PMC:7205724 / 1441-1769 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"51","span":{"begin":69,"end":72},"obj":"Gene"},{"id":"52","span":{"begin":126,"end":129},"obj":"Gene"},{"id":"60","span":{"begin":2,"end":10},"obj":"Species"},{"id":"61","span":{"begin":107,"end":115},"obj":"Species"},{"id":"62","span":{"begin":170,"end":179},"obj":"Species"},{"id":"63","span":{"begin":231,"end":240},"obj":"Species"},{"id":"64","span":{"begin":26,"end":37},"obj":"Chemical"},{"id":"76","span":{"begin":16,"end":24},"obj":"Disease"},{"id":"77","span":{"begin":303,"end":311},"obj":"Disease"}],"attributes":[{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"Gene:3569"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"Gene:3569"},{"id":"A60","pred":"tao:has_database_id","subj":"60","obj":"Tax:9606"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:9606"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:2697049"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"Tax:2697049"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C502936"},{"id":"A76","pred":"tao:has_database_id","subj":"76","obj":"MESH:C000657245"},{"id":"A77","pred":"tao:has_database_id","subj":"77","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T5","span":{"begin":52,"end":60},"obj":"Body_part"},{"id":"T6","span":{"begin":180,"end":184},"obj":"Body_part"},{"id":"T7","span":{"begin":255,"end":268},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T1","span":{"begin":255,"end":268},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T17","span":{"begin":16,"end":24},"obj":"Disease"},{"id":"T18","span":{"begin":170,"end":174},"obj":"Disease"},{"id":"T19","span":{"begin":231,"end":235},"obj":"Disease"},{"id":"T20","span":{"begin":303,"end":311},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T5","span":{"begin":39,"end":40},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T6","span":{"begin":180,"end":184},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T7","span":{"begin":255,"end":268},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T3","span":{"begin":180,"end":184},"obj":"http://purl.obolibrary.org/obo/CL_0000000"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-PD-NCBITaxon","denotations":[{"id":"T17","span":{"begin":16,"end":24},"obj":"Species"},{"id":"T18","span":{"begin":170,"end":179},"obj":"Species"},{"id":"T19","span":{"begin":231,"end":240},"obj":"Species"},{"id":"T20","span":{"begin":303,"end":311},"obj":"Species"}],"attributes":[{"id":"A17","pred":"ncbi_taxonomy_id","subj":"T17","obj":"NCBItxid:2697049"},{"id":"A18","pred":"ncbi_taxonomy_id","subj":"T18","obj":"NCBItxid:2697049"},{"id":"A19","pred":"ncbi_taxonomy_id","subj":"T19","obj":"NCBItxid:2697049"},{"id":"A20","pred":"ncbi_taxonomy_id","subj":"T20","obj":"NCBItxid:2697049"}],"namespaces":[{"prefix":"NCBItxid","uri":"http://purl.bioontology.org/ontology/NCBITAXON/"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T19","span":{"begin":26,"end":137},"obj":"Sentence"},{"id":"T20","span":{"begin":138,"end":320},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-PD-UBERON","denotations":[{"id":"T1","span":{"begin":255,"end":268},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"60","span":{"begin":2,"end":10},"obj":"Species"},{"id":"76","span":{"begin":16,"end":24},"obj":"Disease"},{"id":"64","span":{"begin":26,"end":37},"obj":"Chemical"},{"id":"51","span":{"begin":69,"end":72},"obj":"Gene"},{"id":"61","span":{"begin":107,"end":115},"obj":"Species"},{"id":"52","span":{"begin":126,"end":129},"obj":"Gene"},{"id":"62","span":{"begin":170,"end":179},"obj":"Species"},{"id":"63","span":{"begin":231,"end":240},"obj":"Species"},{"id":"77","span":{"begin":303,"end":311},"obj":"Disease"}],"attributes":[{"id":"A64","pred":"pubann:denotes","subj":"64","obj":"MESH:C502936"},{"id":"A77","pred":"pubann:denotes","subj":"77","obj":"MESH:C000657245"},{"id":"A52","pred":"pubann:denotes","subj":"52","obj":"Gene:3569"},{"id":"A51","pred":"pubann:denotes","subj":"51","obj":"Gene:3569"},{"id":"A60","pred":"pubann:denotes","subj":"60","obj":"Tax:9606"},{"id":"A76","pred":"pubann:denotes","subj":"76","obj":"MESH:C000657245"},{"id":"A62","pred":"pubann:denotes","subj":"62","obj":"Tax:2697049"},{"id":"A63","pred":"pubann:denotes","subj":"63","obj":"Tax:2697049"},{"id":"A61","pred":"pubann:denotes","subj":"61","obj":"Tax:9606"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T177","span":{"begin":69,"end":72},"obj":"Protein"},{"id":"T221","span":{"begin":126,"end":129},"obj":"Protein"}],"attributes":[{"id":"A177","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A178","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A179","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A180","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A181","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A182","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A183","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A184","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A185","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A186","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A187","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A188","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A189","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A190","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A191","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A192","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A193","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A194","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A195","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A196","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A197","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A198","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A199","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A200","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A201","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A202","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A203","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A204","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A205","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A206","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A207","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A208","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A209","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A210","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A211","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A212","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A213","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A214","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A215","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A216","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A217","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A218","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A219","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A220","pred":"uniprot_id","subj":"T177","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A221","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A222","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A223","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A224","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A225","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A226","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A227","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A228","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A229","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A230","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A231","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A232","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A233","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A234","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A235","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A236","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A237","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A238","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A239","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A240","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A241","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A242","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A243","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A244","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A245","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A246","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A247","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A248","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A249","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A250","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A251","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A252","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A253","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A254","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A255","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A256","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A257","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A258","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A259","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A260","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A261","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A262","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A263","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A264","pred":"uniprot_id","subj":"T221","obj":"https://www.uniprot.org/uniprot/A0S0B0"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T219","span":{"begin":2,"end":10},"obj":"NNS"},{"id":"T220","span":{"begin":11,"end":15},"obj":"IN"},{"id":"T221","span":{"begin":16,"end":24},"obj":"NN"},{"id":"T222","span":{"begin":26,"end":37},"obj":"NNP"},{"id":"T223","span":{"begin":37,"end":38},"obj":"-COMMA-"},{"id":"T224","span":{"begin":39,"end":40},"obj":"DT"},{"id":"T225","span":{"begin":41,"end":51},"obj":"JJ"},{"id":"T226","span":{"begin":52,"end":60},"obj":"NN"},{"id":"T227","span":{"begin":61,"end":68},"obj":"IN"},{"id":"T228","span":{"begin":69,"end":72},"obj":"NN"},{"id":"T229","span":{"begin":72,"end":73},"obj":"-COMMA-"},{"id":"T230","span":{"begin":74,"end":79},"obj":"MD"},{"id":"T231","span":{"begin":80,"end":86},"obj":"VB"},{"id":"T232","span":{"begin":87,"end":95},"obj":"JJ"},{"id":"T233","span":{"begin":96,"end":103},"obj":"NN"},{"id":"T234","span":{"begin":104,"end":106},"obj":"IN"},{"id":"T235","span":{"begin":107,"end":115},"obj":"NNS"},{"id":"T236","span":{"begin":116,"end":120},"obj":"IN"},{"id":"T237","span":{"begin":121,"end":125},"obj":"JJ"},{"id":"T238","span":{"begin":126,"end":129},"obj":"NN"},{"id":"T239","span":{"begin":130,"end":136},"obj":"NNS"},{"id":"T240","span":{"begin":138,"end":147},"obj":"JJ"},{"id":"T241","span":{"begin":148,"end":156},"obj":"NNS"},{"id":"T242","span":{"begin":157,"end":161},"obj":"IN"},{"id":"T243","span":{"begin":162,"end":169},"obj":"NN"},{"id":"T244","span":{"begin":170,"end":179},"obj":"NN"},{"id":"T245","span":{"begin":180,"end":184},"obj":"NN"},{"id":"T246","span":{"begin":185,"end":190},"obj":"NN"},{"id":"T247","span":{"begin":191,"end":194},"obj":"CC"},{"id":"T248","span":{"begin":195,"end":203},"obj":"JJ"},{"id":"T249","span":{"begin":204,"end":219},"obj":"NNS"},{"id":"T250","span":{"begin":220,"end":224},"obj":"WDT"},{"id":"T251","span":{"begin":225,"end":230},"obj":"VBP"},{"id":"T252","span":{"begin":231,"end":240},"obj":"NN"},{"id":"T253","span":{"begin":241,"end":243},"obj":"TO"},{"id":"T254","span":{"begin":244,"end":250},"obj":"VB"},{"id":"T255","span":{"begin":251,"end":254},"obj":"DT"},{"id":"T256","span":{"begin":255,"end":261},"obj":"JJ"},{"id":"T257","span":{"begin":262,"end":268},"obj":"NN"},{"id":"T258","span":{"begin":269,"end":273},"obj":"VBP"},{"id":"T259","span":{"begin":274,"end":277},"obj":"DT"},{"id":"T260","span":{"begin":278,"end":287},"obj":"NN"},{"id":"T261","span":{"begin":288,"end":290},"obj":"IN"},{"id":"T262","span":{"begin":291,"end":298},"obj":"NNS"},{"id":"T263","span":{"begin":299,"end":302},"obj":"IN"},{"id":"T264","span":{"begin":303,"end":311},"obj":"NN"},{"id":"T265","span":{"begin":312,"end":319},"obj":"NN"},{"id":"T266","span":{"begin":322,"end":323},"obj":"CD"}],"relations":[{"id":"R245","pred":"arg1Of","subj":"T254","obj":"T253"},{"id":"R246","pred":"arg1Of","subj":"T252","obj":"T254"},{"id":"R248","pred":"arg1Of","subj":"T257","obj":"T255"},{"id":"R249","pred":"arg1Of","subj":"T257","obj":"T256"},{"id":"R250","pred":"arg1Of","subj":"T247","obj":"T258"},{"id":"R251","pred":"arg2Of","subj":"T260","obj":"T258"},{"id":"R252","pred":"arg1Of","subj":"T260","obj":"T259"},{"id":"R253","pred":"arg1Of","subj":"T258","obj":"T261"},{"id":"R211","pred":"arg1Of","subj":"T219","obj":"T220"},{"id":"R212","pred":"arg2Of","subj":"T221","obj":"T220"},{"id":"R213","pred":"arg1Of","subj":"T222","obj":"T223"},{"id":"R214","pred":"arg2Of","subj":"T226","obj":"T223"},{"id":"R215","pred":"arg1Of","subj":"T226","obj":"T224"},{"id":"R216","pred":"arg1Of","subj":"T226","obj":"T225"},{"id":"R217","pred":"arg1Of","subj":"T226","obj":"T227"},{"id":"R218","pred":"arg2Of","subj":"T228","obj":"T227"},{"id":"R219","pred":"arg1Of","subj":"T231","obj":"T229"},{"id":"R220","pred":"arg1Of","subj":"T222","obj":"T230"},{"id":"R221","pred":"arg2Of","subj":"T231","obj":"T230"},{"id":"R222","pred":"arg1Of","subj":"T222","obj":"T231"},{"id":"R223","pred":"arg2Of","subj":"T233","obj":"T231"},{"id":"R224","pred":"arg1Of","subj":"T233","obj":"T232"},{"id":"R225","pred":"arg1Of","subj":"T231","obj":"T234"},{"id":"R226","pred":"arg2Of","subj":"T235","obj":"T234"},{"id":"R227","pred":"arg1Of","subj":"T235","obj":"T236"},{"id":"R228","pred":"arg2Of","subj":"T239","obj":"T236"},{"id":"R229","pred":"arg1Of","subj":"T239","obj":"T237"},{"id":"R230","pred":"arg1Of","subj":"T239","obj":"T238"},{"id":"R231","pred":"arg1Of","subj":"T241","obj":"T240"},{"id":"R232","pred":"arg1Of","subj":"T241","obj":"T242"},{"id":"R233","pred":"arg2Of","subj":"T247","obj":"T242"},{"id":"R234","pred":"arg3Of","subj":"T258","obj":"T242"},{"id":"R235","pred":"arg1Of","subj":"T246","obj":"T243"},{"id":"R236","pred":"arg1Of","subj":"T246","obj":"T244"},{"id":"R237","pred":"arg1Of","subj":"T246","obj":"T245"},{"id":"R238","pred":"arg1Of","subj":"T246","obj":"T247"},{"id":"R239","pred":"arg2Of","subj":"T249","obj":"T247"},{"id":"R240","pred":"arg1Of","subj":"T249","obj":"T248"},{"id":"R241","pred":"arg1Of","subj":"T249","obj":"T250"},{"id":"R242","pred":"arg1Of","subj":"T249","obj":"T251"},{"id":"R243","pred":"arg2Of","subj":"T252","obj":"T251"},{"id":"R244","pred":"arg3Of","subj":"T254","obj":"T251"},{"id":"R247","pred":"arg2Of","subj":"T257","obj":"T254"},{"id":"R254","pred":"arg2Of","subj":"T262","obj":"T261"},{"id":"R255","pred":"arg1Of","subj":"T262","obj":"T263"},{"id":"R256","pred":"arg2Of","subj":"T265","obj":"T263"},{"id":"R257","pred":"arg1Of","subj":"T265","obj":"T264"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T5","span":{"begin":52,"end":60},"obj":"Body_part"},{"id":"T6","span":{"begin":180,"end":184},"obj":"Body_part"},{"id":"T7","span":{"begin":255,"end":268},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"fma_id","subj":"T5","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sample-PD-MONDO","denotations":[{"id":"T17","span":{"begin":16,"end":24},"obj":"Disease"},{"id":"T18","span":{"begin":170,"end":179},"obj":"Disease"},{"id":"T19","span":{"begin":231,"end":240},"obj":"Disease"},{"id":"T20","span":{"begin":303,"end":311},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}

{"project":"LitCovid-sentences","denotations":[{"id":"T19","span":{"begin":26,"end":137},"obj":"Sentence"},{"id":"T20","span":{"begin":138,"end":320},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"f patients with COVID-19. Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. Essential elements that process SARS-CoV2 cell entry and specific characteristics that allow SARS-CoV2 to escape the immune system have the potential as targets for COVID-19 therapy.\n\n1 Int"}